by Annika Kim Constantino for CNBC

“Pfizer on Monday said it would stop developing its experimental obesity and diabetes pill, lotiglipron, due to elevated liver enzymes in patients who took the drug once a day in midstage clinical studies. 

Those elevated enzymes often indicate damage to cells in the liver, but the pharmaceutical giant said no patients experienced liver-related symptoms or side effects. 

Shares of Pfizer closed 3.6% lower on Monday.”

Continue reading at the original source, linked here.